Stay updated with breaking news from Psoriasis Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute...
Wednesday, Matinas BioPharma Holdings Inc (NASDAQ: MTNB) announced results from a series of in vivo studies demonstrating successful oral delivery of two lipid nanocrystal (LNC)-formulated small single-strand oligonucleotides targeting inflammatory cytokines TNFα and IL-17
New data suggests that anti-IL-17A biologics including ixekizumab showed strong self-reported results in signs and symptoms for psoriasis patients.
Results for TAK-279 (Formerly NDI-034858) Show a Significantly Greater Proportion of Patients Achieved Psoriasis Area and Severity Index (PASI) 75 at Doses ≥5mg at 12 Weeks1At the Highest Dose of TAK-279, 46% of Patients Achieved PASI 90 and 33% Achieved PASI 100 at 12 Weeks, Indicating a Near-Total or Total Clearan...